Abstract: Disclosed are a route discovery method and apparatus, a device, and a storage medium. This method includes: receiving a route request packet that is broadcast to a current node; determining whether it is the first time that the current node receives the route request packet; if yes, evaluating, based on link overheads and retransmission overheads, performance of a real-time route and a historical route to obtain an evaluation result; and if the evaluation result indicates that the real-time route is better than the historical route, updating a reverse route of the current node based on the real-time route, to discover a route between a source node and a destination node based on the updated reverse route of the current node. Therefore, link overheads and retransmission overheads are considered in an AODV route discovery process, so that a discovered route has more balanced forward and reverse transmission performance.

Abstract: Use of an aldehyde-based compound as represented by general formula I, a pharmaceutical composition, a pharmaceutical salt, an enantiomer, a diastereomer and a racemic compound thereof as a novel coronavirus 2019 (2019-nCov) 3CL protease inhibitor in preparation of a medicament for treating and/or preventing and relieving respiratory tract infections, pneumonia and other related diseases caused by the novel coronavirus infection 2019.

Abstract: A class of ketoamide-based compounds, in particular, a ketoarnide-based compound as represented by general formula A is provided. The ketoamide compound may be used as a 2019 novel coronavirus (2019-nCov) 3 CL protease inhibitor and/or human cathepsin L inhibitor, and/or may be used in the preparation of a medicament for treating and/or preventing and relieving respiratory tract infection, pneumonia and other related diseases caused by 2019 novel coronavirus infection. Pharmaceutical compositions of the class of compounds, pharmaceutical salts, enantiomeric forms, diastereoisomers and racemic compounds thereof in the preparation of a medicament for treating and/or preventing and relieving respiratory tract infections and other related diseases caused by the 2019 novel coronavirus infection are also provided.